Over 1 000 000 men and women answered a confidential questionnaire and were traced for up to six years afterwards. Among other questions each person was asked how often he or she took aspirin-"never," "seldom," or "often." Coronary heart disease death rates were no lower among people who took aspirin often than among those who did not do so.
Introduction
We undertook this study because of two papers which appeared in the British Medical J7ournal in 1974.13 Both suggested that daily use of aspirin reduces the risk of myocardial infarction. One was a retrospective epidemiological study and the other a clinical trial. The results of the latter, though in the indicated direction, were not statistically significant, and the authors refrained from drawing firm conclusions. Hence we analysed pertinent data already on hand from a prospective epidemiological study.
Subjects and Methods
Starting on 1 October 1959 volunteer workers of the American Cancer Society enrolled over lm. men and women as subjects for a long-term study. All were over the age of 30 and most were over 45. On enrollment each subject answered a long confidential questionnaire, which included questions on family history, disease history, physical complaints, habits, and many other factors. The subjects were traced up to 30 September 1965, and death certificates were obtained on those who died. Further details of the study and some findings in respect to coronary heart disease have been published.3-'
The initial questionnaire contained the question, "How often do you use the following types of medicine?" One of the medicines listed was "aspirin (Bufferin)" and the subject coIuld tick "never," "seldom," or "often." Bufferin is a brand of aspirin widely advertised in the United States. The terms "never" "seldom" and "often" referred to current use rather than lifetime use. Most people ticked "seldomn" (table I) . Proportionately more women than men ticked "often," and the proportion ticking "often" increased with age. Conversely, proportionately more men than women ticked "never," but the overall proportion ticking "never" also increased with age.
Some 30 September 1965. These rates were then applied to person-years of exposure of people in each aspirin-use category ("never," "seldom," and "often") to obtain the expected number of deaths in each of these three categories.
Results
In the first analysis we excluded people who reported a history of heart disease, stroke, diabetes, or high blood pressure. The results in relation to coronary heart disease for all men, men who smoked 20 or more cigarettes a day, and all women are shown in table II. For each sex the observed number of deaths from coronary heart disease was slightly less than the expected number-that is a mortality ratio less than 1 00-among people who seldom took aspirin and slightly greater than the expected number among people who never took aspirin and those who often took aspirin.
Essentially the same relationships were found in respect to deaths ascribed to cerebral vascular lesions. For all deaths (disregarding cause) the mortality ratios were greater than 1 -00 among people who often took aspirin.
Since these findings are very different from those in the published retrospective study,' we made several more analyses to see whether a different handling of the data would yield results more in line with that study. For example, one analysis was the same as that described above but confined to experience during the first 39 months of the study; another included all subjects regardless of past history of disease; another included all subjects but was confined to the 12-month period after the date of enrollment of each subject; and another was confined to the first six-month period. None of these analyses suggested that taking aspirin often was associated with a reduction of death rates from coronary heart disease.
At Dr. H. Jick's suggestion we analysed data on only those people who on the initial questionnaire had said that they had or had had heart disease ( number of subjects in the larger group. The figures for all sets were then summarized. The result was equivalent to carrying out matched-pairs analysis many times over (each time using random numbers to select individual pairs within a set) and then averaging the results. The findings are described below, each figure being rounded off to the nearest whole number. Among men there were 47 047 matched pairs (47 047 aspirinoften subjects matched with 47 047 aspirin not often subjects). During the study 4212 of the "often" subjects died and 3892 of the "not often" subjects died: 1756 of the "oftens" and 1726 of the "not oftens" died of coronary heart disease. Among women there were 102 049 matched pairs, and 4218 "oftens" and 3995 "not oftens" died: 1124 of the "oftens" and 1070 of the "not oftens" died of coronary heart disease. Thus the number of people of both sexes who died of coronary heart disease was slightly higher among those who took aspirin often than among those who did not take aspirin often.
Generally the reported cause of death may be less liable to error if death occurs in hospital than elsewhere. In the United States many deaths attributed to coronary heart disease occur out of hospital, this being commonly so in cases of sudden death. According to Spain,' recent coronary heart thrombi are seldom fotmd at necropsy in sudden and unexpected fatalities from coronary heart disease. For these reasons place of death could have a bearing on interpretation of our findings.
Among men 862 of the "oftens" and 842 of the "not oftens" died in hospital of coronary heart disease; among women, 572 of the "oftens" and 539 of the "not oftens" so died. Among. men 894 of the "oftens" and 884 of the "not oftens" died out of hospital of coronary heart disease, and among women 552 of the "oftens" and 531 of the "not oftens" so died.
Discussion
The Boston Collaborative Drug Surveillance Group reported the results of two similar retrospective studies on use of aspirin in relation to risk of acute myocardial infarction.1 Both studies covered patients admitted to hospital for myocardial infarction while controls consisted of patients admitted to hospital for some other condition, including angina pectoris or coronary insufficiency without evidence of acute myocardial infarction. Regular aspirin users were defined as patients who took aspirin daily (first study) or patients who took aspirin at least four days a week and continued to do so up to the time of admission (second study). The results seemed to indicate that the relative risk of acute myocardial infarction is about one-fifth as high (first study) or about half as high (second study) in regular aspirin users as in other people.
If such be the case it is reasonable to postulate that habitual use of aspirin four days or more a week would result in a substantial reduction in death rates from coronary heart disease. A direct test of this hypothesis would require information on how many days a week each person took aspirin. Lacking this information we ascertained coronary heart disease death rates in relation to aspirin use in terms of "never," "seldom,"
or "often." Presumably people who took aspirin daily or nearly so would say that they took it often. Our results are inconsistent with the hypothesis that taking aspirin often results in reduced death rates from coronary heart disease.
Since this subject is important we are concerned lest our results be misleading. We will discuss some of the possible difficulties.
A major question is how often aspirin was taken by people who said that they took it often. An idea of this can be obtained by comparing our data with data collected by Dr. Jick and his associates.' In the Boston studies patients admitted for diseases likely to lead to heavy use of aspirin-for example, arthritis-were excluded from both subject and control groups.' Dr. Jick has kindly provided us with information showing that the proportion of daily aspirin users was greater among all patients than among those selected for the control group. A comparison of his data with ours suggests that somewhere between one-third and half of our subjects who said that they took aspirin often took it daily or nearly so. This would have a diluting effect on our results if it is true that only regular use of aspirin reduces coronary heart disease death rates.
What concerns us most is the possibility that frequent use of aspirin may not be a fixed habit even among people who have arthritis. Some of the subjects who were taking aspirin often at the time they enrolled in the study may have stopped doing so long before the end of the six-year period and vice versa. It seems reasonable to suppose, however, that such reversal of habits is less likely to occur in a short period of time than in a long period. Thus we made analyses confined to the early part of the study-the first 39 months, the first year after enrollment, and the first six months after enrollment. The results of these analyses did not alter the picture.
Cause of death was ascertained from information on death certificates, which is not always correct. This would tend to dilute the findings, but it seems unlikely that it would reverse the direction of the results. In the Boston study patients admitted to hospital for acute myocardial infarction were compared for use of aspirin with patients in hospital for other conditions. In our study death rates from coronary heart disease weee examined with respect to use of aspirin. "Death due to coronary heart disease" is not synonymous with "acute myocardial infarction."
Having said all this we are still at a loss to explain why-if regular use of aspirin greatly reduces the risk of acute myocardial infarction-death rates from coronary heart disease were no lower among people who took aspirin often than among people who did not do so.
